Rajesh Kumar
Stock Analyst at HSBC
(2.64)
# 2,120
Out of 4,945 analysts
22
Total ratings
60%
Success rate
14.33%
Average return
Main Sectors:
Stocks Rated by Rajesh Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk | Downgrades: Hold | n/a | $50.95 | - | 1 | Jul 31, 2025 | |
| LLY Eli Lilly and Company | Downgrades: Reduce | $1,150 → $700 | $684.43 | +2.27% | 2 | Apr 28, 2025 | |
| IQV IQVIA Holdings | Downgrades: Hold | $260 → $160 | $189.40 | -15.52% | 1 | Apr 25, 2025 | |
| KDP Keurig Dr Pepper | Upgrades: Buy | $36 → $42 | $34.63 | +21.28% | 1 | Apr 25, 2025 | |
| ABBV AbbVie | Upgrades: Buy | $185 | $204.68 | -9.62% | 3 | Jun 5, 2024 | |
| TMO Thermo Fisher Scientific | Maintains: Buy | $660 → $670 | $485.04 | +38.13% | 3 | Apr 30, 2024 | |
| DHR Danaher | Upgrades: Buy | $250 → $280 | $210.22 | +33.19% | 2 | Apr 17, 2024 | |
| UNH UnitedHealth Group | Upgrades: Hold | $460 | $271.50 | +69.43% | 2 | Apr 4, 2024 | |
| TEVA Teva Pharmaceutical Industries | Initiates: Buy | $13 | $17.54 | -25.88% | 1 | Dec 18, 2023 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Hold | $55 → $53 | $47.81 | +10.86% | 2 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Reduce | $97 | $26.69 | +263.43% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $124 | $112.70 | +10.03% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $25.11 | +99.12% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $123 | $82.76 | +48.62% | 1 | Jul 14, 2023 |
Novo Nordisk
Jul 31, 2025
Downgrades: Hold
Price Target: n/a
Current: $50.95
Upside: -
Eli Lilly and Company
Apr 28, 2025
Downgrades: Reduce
Price Target: $1,150 → $700
Current: $684.43
Upside: +2.27%
IQVIA Holdings
Apr 25, 2025
Downgrades: Hold
Price Target: $260 → $160
Current: $189.40
Upside: -15.52%
Keurig Dr Pepper
Apr 25, 2025
Upgrades: Buy
Price Target: $36 → $42
Current: $34.63
Upside: +21.28%
AbbVie
Jun 5, 2024
Upgrades: Buy
Price Target: $185
Current: $204.68
Upside: -9.62%
Thermo Fisher Scientific
Apr 30, 2024
Maintains: Buy
Price Target: $660 → $670
Current: $485.04
Upside: +38.13%
Danaher
Apr 17, 2024
Upgrades: Buy
Price Target: $250 → $280
Current: $210.22
Upside: +33.19%
UnitedHealth Group
Apr 4, 2024
Upgrades: Hold
Price Target: $460
Current: $271.50
Upside: +69.43%
Teva Pharmaceutical Industries
Dec 18, 2023
Initiates: Buy
Price Target: $13
Current: $17.54
Upside: -25.88%
Bristol-Myers Squibb Company
Oct 27, 2023
Upgrades: Hold
Price Target: $55 → $53
Current: $47.81
Upside: +10.86%
Jul 14, 2023
Initiates: Reduce
Price Target: $97
Current: $26.69
Upside: +263.43%
Jul 14, 2023
Initiates: Buy
Price Target: $124
Current: $112.70
Upside: +10.03%
Jul 14, 2023
Initiates: Buy
Price Target: $50
Current: $25.11
Upside: +99.12%
Jul 14, 2023
Initiates: Hold
Price Target: $123
Current: $82.76
Upside: +48.62%